Local

ABC-HCC
A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus trans arterial Chemoembolization (TACE) in intermediate-stage
HCC

IMMUWIN
A phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with either Y-90
SIRT or TACE for intermediate stage HCC with pick-the-winner design

 

Erstlinientherapie

EMERALD-3
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab in combination

Erstlinientherapie

HERIZON-GEA-01 (ZWI-ZW25-301)

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislilizumab in Subjects with Her2-positive unresectable locally advanced or metastatic gastroesophagal adenocarcinoma (GEA)

FORTITUDE-102 (20210098)

A Phase 1b/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab alone in Subjects with previously untreated advanced Gastric and Gastroesophageal Junction cancer with FGFR2b Overexpression.

Adjuvant

BNT122-01              

A multi-site, open-label, Phase II, randomized, controlled trail to compare the efficacy of RO7198457 vs. watchful waiting in resected, Stage II(high risk) and Stage III colorectal  cancer patients who are ctDNA positive following resection

BNT000-001

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up

FIRE-9 / PORT

Prospective, randomized, open-multicenter Phase III to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer, R0/R1 reseziert

Erstlinientherapie

MOUNTAINEER-03 (SGNTUC-029)

An open label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-Line Treatment for Subjects with HER2+ Metastatic Colorectal cancer

Lokal

IMMUWHY

A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Erstlinientherapie

TOURMALINE

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract cancers.

TRAP-BTC

Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer

Zweit- und Drittlinientherapie

Brightline-2 (1403-0011)

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for Treatment of patients with locally advanced/metastatic, MDM2 amplifed, TP53 wildtype biliary tract adenocarcinoma (Arm geschlossen), pancreatic ductal adenocarcinoma (Arm vollständig rekrutiert), or other selected solid tumors. Lunge offen!